Dupilumab in papuloerythroderma of Ofuji: therapeutic efficacy and paradoxical flares in a case-based review

Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the 'deck-chair sign' and is diagnosed according to the criteria proposed by Torchia et al. in 2009. This study aims to summarize the clinical manifestations, emerging treatments, and prognosis of PEO, and to explore the...

Full description

Saved in:

Bibliographic Details
Published in:	The Journal of dermatological treatment Vol. 36; no. 1; p. 2562300
Main Authors:	Liu, Teng, Zhang, Meixi, Gao, Xiaoman, Yang, Kun, Bao, Yingqiu, Zhang, Qiuli, Chang, Jianmin
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis Group 01.12.2025
Subjects:	Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Dermatitis, Exfoliative - diagnosis Dermatitis, Exfoliative - drug therapy Dermatologic Agents - administration & dosage Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use dupilumab Female Humans Male Middle Aged Papuloerythroderma of Ofuji Symptom Flare Up treatment Treatment Outcome tripterygium glycosides treatment tripterygium glycosides Papuloerythroderma of Ofuji dupilumab
ISSN:	0954-6634, 1471-1753, 1471-1753
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the 'deck-chair sign' and is diagnosed according to the criteria proposed by Torchia et al. in 2009. This study aims to summarize the clinical manifestations, emerging treatments, and prognosis of PEO, and to explore the efficacy and paradoxical flares associated with dupilumab treatment. We report two cases associated with dupilumab treatment and conducted a search of PubMed, Embase, the China Knowledge Resource Integrated, and the Wanfang databases using the keywords 'papuloerythroderma of Ofuji' for the period from July 2009 to October 2024. A total of 52 patients were included, with onset most commonly occurring in their 70s. The systemic treatments included dupilumab ( = 7), cyclosporine ( = 6), oral glucocorticoids ( = 5), acitretin ( = 4), methotrexate ( = 3), and apremilast ( = 1). Dupilumab was administered to seven patients, and the skin lesions improved within a short period. No adverse effects were reported in three patients, although elevated eosinophil counts accompanied by worsening lesions were observed in one patient. Our findings suggest that dupilumab is the most commonly utilized treatment for PEO; however, elevated eosinophil counts and potential exacerbation of clinical symptoms warrant attention. Additionally, Tripterygium glycosides may be an effective therapy to improve these conditions.
AbstractList	Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the 'deck-chair sign' and is diagnosed according to the criteria proposed by Torchia et al. in 2009. This study aims to summarize the clinical manifestations, emerging treatments, and prognosis of PEO, and to explore the efficacy and paradoxical flares associated with dupilumab treatment.OBJECTIVESPapuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the 'deck-chair sign' and is diagnosed according to the criteria proposed by Torchia et al. in 2009. This study aims to summarize the clinical manifestations, emerging treatments, and prognosis of PEO, and to explore the efficacy and paradoxical flares associated with dupilumab treatment.We report two cases associated with dupilumab treatment and conducted a search of PubMed, Embase, the China Knowledge Resource Integrated, and the Wanfang databases using the keywords 'papuloerythroderma of Ofuji' for the period from July 2009 to October 2024.METHODSWe report two cases associated with dupilumab treatment and conducted a search of PubMed, Embase, the China Knowledge Resource Integrated, and the Wanfang databases using the keywords 'papuloerythroderma of Ofuji' for the period from July 2009 to October 2024.A total of 52 patients were included, with onset most commonly occurring in their 70s. The systemic treatments included dupilumab (n = 7), cyclosporine (n = 6), oral glucocorticoids (n = 5), acitretin (n = 4), methotrexate (n = 3), and apremilast (n = 1). Dupilumab was administered to seven patients, and the skin lesions improved within a short period. No adverse effects were reported in three patients, although elevated eosinophil counts accompanied by worsening lesions were observed in one patient.RESULTSA total of 52 patients were included, with onset most commonly occurring in their 70s. The systemic treatments included dupilumab (n = 7), cyclosporine (n = 6), oral glucocorticoids (n = 5), acitretin (n = 4), methotrexate (n = 3), and apremilast (n = 1). Dupilumab was administered to seven patients, and the skin lesions improved within a short period. No adverse effects were reported in three patients, although elevated eosinophil counts accompanied by worsening lesions were observed in one patient.Our findings suggest that dupilumab is the most commonly utilized treatment for PEO; however, elevated eosinophil counts and potential exacerbation of clinical symptoms warrant attention. Additionally, Tripterygium glycosides may be an effective therapy to improve these conditions.CONCLUSIONSOur findings suggest that dupilumab is the most commonly utilized treatment for PEO; however, elevated eosinophil counts and potential exacerbation of clinical symptoms warrant attention. Additionally, Tripterygium glycosides may be an effective therapy to improve these conditions. Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the 'deck-chair sign' and is diagnosed according to the criteria proposed by Torchia et al. in 2009. This study aims to summarize the clinical manifestations, emerging treatments, and prognosis of PEO, and to explore the efficacy and paradoxical flares associated with dupilumab treatment. We report two cases associated with dupilumab treatment and conducted a search of PubMed, Embase, the China Knowledge Resource Integrated, and the Wanfang databases using the keywords 'papuloerythroderma of Ofuji' for the period from July 2009 to October 2024. A total of 52 patients were included, with onset most commonly occurring in their 70s. The systemic treatments included dupilumab ( = 7), cyclosporine ( = 6), oral glucocorticoids ( = 5), acitretin ( = 4), methotrexate ( = 3), and apremilast ( = 1). Dupilumab was administered to seven patients, and the skin lesions improved within a short period. No adverse effects were reported in three patients, although elevated eosinophil counts accompanied by worsening lesions were observed in one patient. Our findings suggest that dupilumab is the most commonly utilized treatment for PEO; however, elevated eosinophil counts and potential exacerbation of clinical symptoms warrant attention. Additionally, Tripterygium glycosides may be an effective therapy to improve these conditions. Objectives Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the ‘deck-chair sign’ and is diagnosed according to the criteria proposed by Torchia et al. in 2009. This study aims to summarize the clinical manifestations, emerging treatments, and prognosis of PEO, and to explore the efficacy and paradoxical flares associated with dupilumab treatment.Methods We report two cases associated with dupilumab treatment and conducted a search of PubMed, Embase, the China Knowledge Resource Integrated, and the Wanfang databases using the keywords ‘papuloerythroderma of Ofuji’ for the period from July 2009 to October 2024.Results A total of 52 patients were included, with onset most commonly occurring in their 70s. The systemic treatments included dupilumab (n = 7), cyclosporine (n = 6), oral glucocorticoids (n = 5), acitretin (n = 4), methotrexate (n = 3), and apremilast (n = 1). Dupilumab was administered to seven patients, and the skin lesions improved within a short period. No adverse effects were reported in three patients, although elevated eosinophil counts accompanied by worsening lesions were observed in one patient.Conclusions Our findings suggest that dupilumab is the most commonly utilized treatment for PEO; however, elevated eosinophil counts and potential exacerbation of clinical symptoms warrant attention. Additionally, Tripterygium glycosides may be an effective therapy to improve these conditions.
Author	Liu, Teng Yang, Kun Zhang, Meixi Chang, Jianmin Gao, Xiaoman Bao, Yingqiu Zhang, Qiuli
Author_xml	– sequence: 1 givenname: Teng surname: Liu fullname: Liu, Teng – sequence: 2 givenname: Meixi surname: Zhang fullname: Zhang, Meixi – sequence: 3 givenname: Xiaoman surname: Gao fullname: Gao, Xiaoman – sequence: 4 givenname: Kun surname: Yang fullname: Yang, Kun – sequence: 5 givenname: Yingqiu surname: Bao fullname: Bao, Yingqiu – sequence: 6 givenname: Qiuli surname: Zhang fullname: Zhang, Qiuli – sequence: 7 givenname: Jianmin surname: Chang fullname: Chang, Jianmin
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/40995751$$D View this record in MEDLINE/PubMed
BookMark	eNo9kU1v1DAQhi1URLeFnwDykUsWfyZrbqh8VarUC5ytyXhMs0riYG8o--9J2G0vM9Loed_RzHvFLsY0EmNvpdhKsRMfhLOmrrXZKqHsVtlaaSFesI00jaxkY_UF26xMtUKX7KqUvRBS12L3il0a4ZxtrNyw_vM8df08QMu7kU8wzX2ifDw85BQoD8BT5Pdx3ncf-eGBMkw0HzrkFGOHgEcOY1hUGUL6uwx6HnvIVFYv4AiFqnYpgWf609Hja_YyQl_ozblfs59fv_y4-V7d3X-7vfl0V6Fu1KFC2zRG2DaSCxKFJXQtNg41KleHQMFSK8g1Jip0ChFjbLWQiM2i2CHpa3Z78g0J9n7K3QD56BN0_v8g5V8e8nJGT17BIpCmhhBqo6Vsg3FGkzUKaxVgt3i9P3lNOf2eqRz80BWkvoeR0ly8VtZIZYXQC_rujM7tQOF58dO3F8CeAMyplEzxGZHCr6n6p1T9mqo_p6r_AW05lfo
Cites_doi	10.1111/dth.15852 10.1159/000537837 10.4103/ijd.ijd_201_22 10.1159/000301915 10.1159/000249586 10.1001/jamadermatol.2019.0109 10.1001/jamadermatol.2019.2613 10.1111/phpp.12441 10.1111/jdv.16581 10.1684/ejd.2023.4530 10.1016/j.clindermatol.2020.10.017 10.1080/09546634.2019.1689227 10.18176/jiaci.0823 10.1007/s40629-022-00236-3 10.1358/dot.2017.53.9.2693150 10.1159/000358588 10.1093/ced/llad265 10.2340/actadv.v104.40220 10.5582/ddt.2022.01046 10.1111/ced.14457 10.1111/ajd.14078 10.1046/j.1440-1592.2000.00156.x 10.1111/dth.12638 10.3390/biom12121743 10.1080/13880209.2023.2169468 10.1159/000524716 10.1001/jamadermatol.2019.0946 10.1016/j.jdcr.2024.08.003
ContentType	Journal Article
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA
DOI	10.1080/09546634.2025.2562300
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1471-1753
ExternalDocumentID	oai_doaj_org_article_2a8ce146add64311bd4943e542c62da8 40995751 10_1080_09546634_2025_2562300
Genre	Journal Article Review Case Reports
GroupedDBID	--- 00X 03L 0YH 29K 36B 4.4 5GY AALUX AAYXX ABBKH ABDBF ABEIZ ABLKL ABUPF ABWVI ABXYU ACENM ACGEJ ACGFS ACUHS ADCVX ADRBQ ADXPE AECIN AENEX AEOZL AFKVX AFRVT AGDLA AGYJP AIJEM AJWEG AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AQTUD BABNJ BLEHA BOHLJ CCCUG CITATION CS3 D-I DKSSO DU5 EAP EBC EBD EBS EMB EMK EMOBN EPL ESX F5P GROUPED_DOAJ H13 HZ~ KRBQP KSSTO KWAYT KYCEM LJTGL M4Z O9- P2P SV3 TDBHL TFDNU TFL TFW TUROJ TUS UEQFS V1S ~1N 53G 5VS AAGDL AAJKZ AALIY AAMIU AAORF AAPUL AAPXX AAQRR ABJNI ABLIJ ABWCV ABZEW ACKZS ACOPL ACYZI ADFOM ADFZZ AEIIZ AFLEI AGFJD AGRBW AJVHN AMDAE AWYRJ BRMBE CAG CGR COF CUY CVF CYYVM CZDIS DRXRE DWTOO ECM EIF EJD JENTW M44 NPM NUSFT QQXMO RNANH RVRKI TBQAZ TERGH 7X8
ID	FETCH-LOGICAL-c372t-c577405bfe9d1c05ec9bc79c3c296dded5eb0e974f2c92cccffb301cc7fe98ce3
IEDL.DBID	DOA
ISICitedReferencesCount	0
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001578908000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0954-6634 1471-1753
IngestDate	Fri Oct 03 12:52:52 EDT 2025 Thu Sep 25 20:43:48 EDT 2025 Sun Sep 28 01:42:02 EDT 2025 Sat Nov 29 07:26:55 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	treatment tripterygium glycosides Papuloerythroderma of Ofuji dupilumab
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c372t-c577405bfe9d1c05ec9bc79c3c296dded5eb0e974f2c92cccffb301cc7fe98ce3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Review-5 content type line 23 ObjectType-Case Study-4 ObjectType-Feature-2 ObjectType-Report-3
OpenAccessLink	https://doaj.org/article/2a8ce146add64311bd4943e542c62da8
PMID	40995751
PQID	3254125003
PQPubID	23479
ParticipantIDs	doaj_primary_oai_doaj_org_article_2a8ce146add64311bd4943e542c62da8 proquest_miscellaneous_3254125003 pubmed_primary_40995751 crossref_primary_10_1080_09546634_2025_2562300
PublicationCentury	2000
PublicationDate	2025-Dec
PublicationDateYYYYMMDD	2025-12-01
PublicationDate_xml	– month: 12 year: 2025 text: 2025-Dec
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	The Journal of dermatological treatment
PublicationTitleAlternate	J Dermatolog Treat
PublicationYear	2025
Publisher	Taylor & Francis Group
Publisher_xml	– name: Taylor & Francis Group
References	e_1_3_6_11_1 e_1_3_6_10_1 e_1_3_6_15_1 e_1_3_6_14_1 e_1_3_6_13_1 e_1_3_6_12_1 e_1_3_6_19_1 e_1_3_6_18_1 e_1_3_6_17_1 e_1_3_6_16_1 e_1_3_6_20_1 e_1_3_6_21_1 e_1_3_6_22_1 e_1_3_6_2_1 e_1_3_6_6_1 e_1_3_6_5_1 e_1_3_6_4_1 e_1_3_6_3_1 e_1_3_6_9_1 e_1_3_6_8_1 e_1_3_6_7_1 e_1_3_6_27_1 e_1_3_6_28_1 e_1_3_6_29_1 e_1_3_6_23_1 e_1_3_6_24_1 e_1_3_6_25_1 e_1_3_6_26_1
References_xml	– ident: e_1_3_6_12_1 doi: 10.1111/dth.15852 – ident: e_1_3_6_28_1 doi: 10.1159/000537837 – ident: e_1_3_6_4_1 doi: 10.4103/ijd.ijd_201_22 – ident: e_1_3_6_3_1 doi: 10.1159/000301915 – ident: e_1_3_6_2_1 doi: 10.1159/000249586 – ident: e_1_3_6_24_1 doi: 10.1001/jamadermatol.2019.0109 – ident: e_1_3_6_25_1 doi: 10.1001/jamadermatol.2019.2613 – ident: e_1_3_6_9_1 doi: 10.1111/phpp.12441 – ident: e_1_3_6_18_1 doi: 10.1111/jdv.16581 – ident: e_1_3_6_8_1 doi: 10.1684/ejd.2023.4530 – ident: e_1_3_6_7_1 doi: 10.1016/j.clindermatol.2020.10.017 – ident: e_1_3_6_20_1 doi: 10.1080/09546634.2019.1689227 – ident: e_1_3_6_23_1 doi: 10.18176/jiaci.0823 – ident: e_1_3_6_11_1 doi: 10.1007/s40629-022-00236-3 – ident: e_1_3_6_19_1 doi: 10.1358/dot.2017.53.9.2693150 – ident: e_1_3_6_6_1 doi: 10.1159/000358588 – ident: e_1_3_6_13_1 doi: 10.1093/ced/llad265 – ident: e_1_3_6_15_1 doi: 10.2340/actadv.v104.40220 – ident: e_1_3_6_22_1 doi: 10.5582/ddt.2022.01046 – ident: e_1_3_6_5_1 doi: 10.1111/ced.14457 – ident: e_1_3_6_14_1 doi: 10.1111/ajd.14078 – ident: e_1_3_6_29_1 doi: 10.1046/j.1440-1592.2000.00156.x – ident: e_1_3_6_10_1 doi: 10.1111/dth.12638 – ident: e_1_3_6_26_1 doi: 10.3390/biom12121743 – ident: e_1_3_6_27_1 doi: 10.1080/13880209.2023.2169468 – ident: e_1_3_6_16_1 doi: 10.1159/000524716 – ident: e_1_3_6_17_1 doi: 10.1001/jamadermatol.2019.0946 – ident: e_1_3_6_21_1 doi: 10.1016/j.jdcr.2024.08.003
SSID	ssj0013608
Score	2.399761
SecondaryResourceType	review_article
Snippet	Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the 'deck-chair sign' and is diagnosed according to the criteria proposed by Torchia... Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the 'deck-chair sign' and is diagnosed according to the criteria proposed by Torchia et... Objectives Papuloerythroderma of Ofuji (PEO) is a rare disorder characterized by the ‘deck-chair sign’ and is diagnosed according to the criteria proposed by...
SourceID	doaj proquest pubmed crossref
SourceType	Open Website Aggregation Database Index Database
StartPage	2562300
SubjectTerms	Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Dermatitis, Exfoliative - diagnosis Dermatitis, Exfoliative - drug therapy Dermatologic Agents - administration & dosage Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use dupilumab Female Humans Male Middle Aged Papuloerythroderma of Ofuji Symptom Flare Up treatment Treatment Outcome tripterygium glycosides
Title	Dupilumab in papuloerythroderma of Ofuji: therapeutic efficacy and paradoxical flares in a case-based review
URI	https://www.ncbi.nlm.nih.gov/pubmed/40995751 https://www.proquest.com/docview/3254125003 https://doaj.org/article/2a8ce146add64311bd4943e542c62da8
Volume	36
WOSCitedRecordID	wos001578908000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-1753 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013608 issn: 0954-6634 databaseCode: DOA dateStart: 20230101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAWR databaseName: Taylor & Francis Free Journals (Free resource, activated by CARLI) customDbUrl: eissn: 1471-1753 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013608 issn: 0954-6634 databaseCode: 0YH dateStart: 20231201 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1471-1753 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0013608 issn: 0954-6634 databaseCode: TFW dateStart: 19890101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BhSouiFfpFqiMxDVt4thJzI3XigO0PRTYW2SPbWmrVbLabhD9953Jo9pLxYVLDlYezrxH4_kG4L2xudOIlKlqkmCFJk9sForEyMoqTJ1RPU7Br-_l2Vm1WJiLnVFffCZsgAceCHcqbYWB1Jn0kJxnljmvjMqDVhIL6W3f5ktRz5RMTfWDop9FR_GDSsinqql3h1G1aY2XKDeU-kSy_-f2th2v1IP33x9x9p5n_hSejCGj-Dhs9Rk8CM1z2P8xFsVfwOpLt16SjbFOLBuxtutu1YbNDQ9A8Gx3RRvFeeyulh_ETreVCAweYfFG2MYLRgD37V_mmIgr7knid1mB5OQS9nReDE0uL-Hn_Ovl52_JOEQhwbyU2wQ1BXipdjEYn2GqAxqHpcEcpSnItnkdXBooq4gSjUTEGB0pPWJJTxDp8wPYa9omHILQZSyyGE0pC2ZC5WLUPo9R-Zgi8XwGJxMR6_WAlVFnEwTpSPWaqV6PVJ_BJyb13c0Mdd0vkADUowDU_xKAGbybGFWTanC9wzah7a7rnJJfit_Ibs3g1cDBu09RWmu45HT0P7bwGh7zbw2nXN7A3nbThbfwCP9sl9ebY3hYLqrjXj7pejn_fQsmHeeQ
linkProvider	Directory of Open Access Journals
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dupilumab+in+papuloerythroderma+of+Ofuji%3A+therapeutic+efficacy+and+paradoxical+flares+in+a+case-based+review&rft.jtitle=The+Journal+of+dermatological+treatment&rft.au=Liu%2C+Teng&rft.au=Zhang%2C+Meixi&rft.au=Gao%2C+Xiaoman&rft.au=Yang%2C+Kun&rft.date=2025-12-01&rft.issn=0954-6634&rft.eissn=1471-1753&rft.volume=36&rft.issue=1&rft_id=info:doi/10.1080%2F09546634.2025.2562300&rft.externalDBID=n%2Fa&rft.externalDocID=10_1080_09546634_2025_2562300
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0954-6634&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0954-6634&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0954-6634&client=summon